Boemer, François
Caberg, Jean-Hubert
Beckers, Pablo
Dideberg, Vinciane
di Fiore, Samantha
Bours, Vincent
Marie, Sandrine
Dewulf, Joseph
Marcelis, Lionel
Deconinck, Nicolas
Daron, Aurore
Blasco-Perez, Laura
Tizzano, Eduardo
Hiligsmann, Mickaël
Lombet, Jacques
Pereira, Tatiana
Lopez-Granados, Lucia
Shalchian-Tehran, Sarvnaz
van Assche, Véronique
Willems, Arabelle
Huybrechts, Sofie
Mast, Bénédicte
van Olden, Rudolf
Dangouloff, Tamara
Servais, Laurent
Funding for this research was provided by:
Biogen
Roche
AveXis
ABMM
Article History
Received: 13 April 2021
Accepted: 27 September 2021
First Online: 7 October 2021
Competing interests
: L.S. is member of Biogen, AveXis, Roche, and Cytokinetics scientific advisory boards and has provided consultancy to Roche, AveXis, and Biogen. E.T. has received grant support to conduct clinical trials on SMA from Ionis/Biogen and serves as a consultant to AveXis, Novartis, Biogen, Biologix, Cytokinetics, Roche. A.D. is investigator of SMA studies for Roche and Novartis Gene Therapies and received honoraria for consultancy for the scientific advisory board of AveXis Belgium. B.M. is an employee of Roche. S.H. is an employee of and has stock/stock options in Biogen. R.V.O. is employee of Novartis Gene Therapies and owns Novartis stock or other equities. T.D. and F.B. have given lectures sponsored by Biogen, Novartis and Roche. The other authors have no financial disclosures relevant to this article.